Search clinical trials for: JTZ-951

Total 778 results

Akros Pharma Inc.

Completed

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

Anemia of Chronic Kidney Disease

United States
Akros Pharma Inc.

Completed

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

Anemia in Chronic Kidney Disease

United States
Akros Pharma Inc.

Completed

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

Anemia of Chronic Kidney Disease

United States
JW Pharmaceutical

Completed

A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.

Anemia of Chronic Kidney Disease

Korea, Republic of
Akros Pharma Inc.

Withdrawn

Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension (RELIEF-PAH)

Pulmonary Arterial Hypertension
Akros Pharma Inc.

Completed

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

Diabetes Mellitus

United States
Akros Pharma Inc.

Terminated

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR-PS)

Skin Diseases | Plaque Psoriasis

United States, Canada
Akros Pharma Inc.

Completed

Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis (MOVE-RA)

Rheumatoid Arthritis

Ukraine, United States, Argentina, Bulgaria, Romania, Peru, Russian Federation, Mexico, Colombia, Poland
Akros Pharma Inc.

Completed

Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects

Skin Diseases | Psoriasis | Plaque Psoriasis

Canada
Akros Pharma Inc.

Completed

Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

Anemia of Chronic Kidney Disease

United States
Akros Pharma Inc.

Completed

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS)

Skin Diseases | Psoriasis | Plaque Psoriasis

United States, Canada, Poland
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteers

United States
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteer

United States
Hoya Surgical Optics, Inc.

Completed

Visual Quality Following Aspheric Intraocular Lens (IOL) Implantation - a Comparative Clinical Study (751)

Cataract | Aphakia

Australia
AbbVie

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Parkinson's Disease (PD)

United States
AVEO Pharmaceuticals, Inc.

Completed

An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
Massachusetts General Hospital
National Comprehensive Cancer Network

Completed

Tivozanib for Recurrent Glioblastoma

Glioblastoma

United States
Emory University
AVEO Pharmaceuticals, Inc.

Terminated

Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer

Hepatocellular Cancer

United States
AVEO Pharmaceuticals, Inc.

Completed

A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects

Food Effect of Tivozanib in Health Subjects

United States
AVEO Pharmaceuticals, Inc.

Completed

Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers

Colorectal Cancer | Gastrointestinal Cancer

Netherlands
Dana-Farber Cancer Institute
National Comprehensive Cancer Network; AVEO Pharmaceuticals, Inc.

Terminated

Tivozanib As Maintenance Therapy In GYN

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States
Northwestern University
National Comprehensive Cancer Network

Completed

Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (TIVO)

Recurrent Fallopian Tube Cancer | Recurrent Epithelial Ovarian Cancer | Recurrent Primary Peritoneal Cancer

United States
Roswell Park Cancer Institute
AVEO Pharmaceuticals, Inc.

Withdrawn

Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer

Stage III Renal Cell Cancer | Stage II Renal Cell Cancer
Northwestern University
AVEO Pharmaceuticals, Inc.

Completed

A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma

United States
AVEO Pharmaceuticals, Inc.

Terminated

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

Solid Tumors

United States, Canada, Netherlands, India, Russian Federation, Ukraine
AbbVie

Completed

A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

Parkinson's Disease (PD)

United States
Jounce Therapeutics, Inc.

Active, not recruiting

Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (SELECT)

NSCLC

Turkey, Latvia, Serbia, Ukraine, Russian Federation, Romania, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Georgia, Hungary, Moldova, Republic of, Slovakia
AVEO Pharmaceuticals, Inc.

Completed

A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma

Carcinoma, Renal Cell

Ukraine, India, Russian Federation
AbbVie

Completed

Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease

Parkinson's Disease

United States
T3D Therapeutics, Inc.
National Institute on Aging (NIA); Alzheimer's Association; Clinilabs, Inc.

Completed

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

Alzheimer Disease

United States
Akros Pharma Inc.

Terminated

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

Diabetes Mellitus

United States
Tulane University Health Sciences Center

Completed

Trichomonas Vaginalis Repeat Infections Among HIV Negative Women

Vaginitis Trichomonal or Due to Trichomonas

United States
Akros Pharma Inc.

Completed

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network; AVEO...

Completed

Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery

Advanced Adult Hepatocellular Carcinoma | Non-Resectable Hepatocellular Carcinoma

United States
University of Sydney
University of Pennsylvania; University of California, San Diego; University of... and other collaborators

Completed

Appropriate Oxygen Levels for Extremely Preterm Infants: a Prospective Meta-analysis (NeOProM)

Infant, Newborn, Diseases | Infant, Premature, Diseases | Retinopathy of Prematurity | Bronchopulmonary Dysplasia | Infant, Very Low Birth Weight

Australia
Akros Pharma Inc.

Completed

Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects

Hepatitis C Virus Infection, Response to Therapy of

Puerto Rico
AbbVie

Completed

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom
Akros Pharma Inc.

Completed

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

Type II Diabetes Mellitus

United States, Russian Federation, Czech Republic, Hungary, Netherlands
TYK Medicines, Inc

Active, not recruiting

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

NSCLC | Brain Metastases | EGFR Activating Mutation | Leptomeningeal Metastasis

China
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

Postoperative Gastrointestinal Dysfunction

United States, Germany
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

Healthy Volunteers

United States
CK Regeon Inc.

Completed

Safety, Tolerability, and Pharmacokinetic Evaluations of CKR-051 After Transdermal Administration in Healthy Male Subjects

Healthy

Korea, Republic of
Akros Pharma Inc.

Terminated

Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients

Type II Diabetes Mellitus

United States
AbbVie

Active, not recruiting

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom
AbbVie

Active, not recruiting

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia
Fuji Yakuhin Co., Ltd.

Completed

Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)

Hyperuricemia

Japan
Arcutis Biotherapeutics, Inc.

Completed

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-I)

Atopic Dermatitis Eczema

United States, Canada
Arcutis Biotherapeutics, Inc.

Completed

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

Atopic Dermatitis Eczema

United States, Canada
TYK Medicines, Inc

Recruiting

[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects

Healthy Volunteers

China
Akros Pharma Inc.

Completed

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Dyslipidemia

United States

Search clinical trials for: JTZ-951

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations